{"id":551270,"date":"2026-04-01T22:50:07","date_gmt":"2026-04-01T20:50:07","guid":{"rendered":"https:\/\/medizinonline.com\/nuovi-standard-terapeutici-con-shr-a-1811\/"},"modified":"2026-04-01T22:50:43","modified_gmt":"2026-04-01T20:50:43","slug":"nuovi-standard-terapeutici-con-shr-a-1811","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/it\/nuovi-standard-terapeutici-con-shr-a-1811\/","title":{"rendered":"Nuovi standard terapeutici con SHR-A 1811"},"content":{"rendered":"\n<p><strong>Il Congresso ESMO 2025 di quest&#8217;anno ha offerto ancora una volta un&#8217;ampia gamma di nuovi dati sul trattamento del carcinoma mammario HER2-positivo, tra cui l&#8217;analisi ad interim dello studio di fase 3 HORIZON-Breast01 presentata da Erwei Song (Sun Yat-sen University, Guangzhou). Lo studio confronta SHR-A 1811 con pirotinib pi\u00f9 capecitabina nelle pazienti con carcinoma mammario metastatico HER2-positivo. Fornisce i primi dati randomizzati su questo nuovo coniugato anticorpo-farmaco mirato a HER2.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fnuovi-standard-terapeutici-con-shr-a-1811%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Il Congresso ESMO 2025 di quest&#8217;anno ha offerto ancora una volta un&#8217;ampia gamma di nuovi dati sul trattamento del carcinoma mammario HER2-positivo, tra cui l&#8217;analisi ad interim dello studio di&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fnuovi-standard-terapeutici-con-shr-a-1811%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":551273,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cancro al seno metastatizzato HER2+  ","footnotes":""},"category":[11409,11376,11522,11550,11515],"tags":[90002,13612,90001,17501,90009,22531,90005,89988,89993,89998,90007,89991,90008,89995,89997,90006],"powerkit_post_featured":[],"class_list":["post-551270","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ginecologia-it","category-oncologia-it","category-rapporti-del-congresso","category-rx-it","category-studi","tag-analisi-ad-interim-studio-di-fase-3-horizon-breast01","tag-cancro-al-seno","tag-cancro-al-seno-metastatico-her2-positivo","tag-capecitabina-it","tag-congresso-esmo-2025","tag-esmo-it","tag-nuovi-coniugati-anticorpo-farmaco-mirati-a-her2","tag-pirotinib","tag-pirotinib-piu-capecitabina","tag-profilo-degli-effetti-collaterali-shr-a-1811-vs-pirotinib-capecitabina","tag-sequenziamento-delle-terapie-dirette-a-her2","tag-shr-a-1811","tag-shr-a1811-trastuzumab-rezetecan","tag-studio-di-fase-1-horizon-x","tag-studio-pehdra","tag-studio-phoebe","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-28 01:48:00","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"it_IT","wpml_translations":{"pt_PT":{"locale":"pt_PT","id":551276,"slug":"novos-padroes-terapeuticos-com-o-shr-a-1811","post_title":"Novos padr\u00f5es terap\u00eauticos com o SHR-A 1811","href":"https:\/\/medizinonline.com\/pt-pt\/novos-padroes-terapeuticos-com-o-shr-a-1811\/"},"es_ES":{"locale":"es_ES","id":551287,"slug":"nuevos-estandares-terapeuticos-con-shr-a-1811","post_title":"Nuevos est\u00e1ndares terap\u00e9uticos con SHR-A 1811","href":"https:\/\/medizinonline.com\/es\/nuevos-estandares-terapeuticos-con-shr-a-1811\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/551270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/comments?post=551270"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/551270\/revisions"}],"predecessor-version":[{"id":551275,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/551270\/revisions\/551275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media\/551273"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media?parent=551270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/category?post=551270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/tags?post=551270"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/powerkit_post_featured?post=551270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}